Cargando…

Early Adalimumab and Anti‐Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients

This study aimed at exploring the concentration‐effect relationship of adalimumab and early adalimumab and anti‐adalimumab antibody (AAA) levels in predicting primary nonresponse in a real‐world pilot cohort of patients with ankylosing spondylitis. Thirty‐one patients were included. The Ankylosing S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Xiaoliang, Zhu, Ruifang, Wu, Jian, Xue, Ling, Gu, Meihua, Miao, Liyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214645/ https://www.ncbi.nlm.nih.gov/pubmed/31961477 http://dx.doi.org/10.1111/cts.12738

Ejemplares similares

Efficacy and safety of adalimumab in ankylosing spondylitis
por: Mounach, Aziza, et al.
Publicado: (2014)

Adalimumab Therapy Restores the Gut Microbiota in Patients With Ankylosing Spondylitis
por: Chen, Zena, et al.
Publicado: (2021)

Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

Adalimumab Mitigates Lumbar Radiculopathy in a Case of Ankylosing Spondylitis
por: Persaud, Trevor, et al.
Publicado: (2022)

A Case of Adalimumab-Induced Psoriasiform Dermatitis in an Ankylosing Spondylitis Patient: Unusual Progression after Adalimumab Retreatment
por: Yoon, Ji Ha, et al.
Publicado: (2022)

Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy
por: Hennigan, Stephanie, et al.
Publicado: (2007)

Palmoplantar Pustulosis Induced by both Adalimumab and Golimumab for Treatment of Ankylosing Spondylitis
por: Seol, Jung Eun, et al.
Publicado: (2016)

Improvement of overlapping hidradenitis suppurativa and ankylosing spondylitis after the introduction of adalimumab
por: Bosnić, Dubravka, et al.
Publicado: (2016)

Allergic bronchopulmonary aspergillosis in a patient with ankylosing spondylitis treated with adalimumab
por: Suzuki, Yudai, et al.
Publicado: (2021)

Frequency of peripheral diseases in Korean patients with ankylosing spondylitis and the effectiveness of adalimumab
por: Lee, Sang‐Hoon, et al.
Publicado: (2020)

Eosinophilia in a patient with ankylosing spondylitis treated with prolonged adalimumab only
por: He, Junhong, et al.
Publicado: (2022)

Reactive Arthritis Triggered by Adalimumab and Leflunomide in a Patient with Ankylosing Spondylitis
por: Liu, Ying, et al.
Publicado: (2022)

Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis
por: Rudwaleit, Martin, et al.
Publicado: (2010)

The Long-Term Effects of Short-Period Adalimumab Biosimilar Usage in Ankylosing Spondylitis
por: Chopra, Arvind, et al.
Publicado: (2023)

Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison
por: Maksymowych, Walter P., et al.
Publicado: (2018)

Lobular capillary hemangioma in a patient with ankylosing spondylitis using adalimumab: an exuberant presentation()()
por: Silva, Thadeu Santos, et al.
Publicado: (2019)

Optical coherence tomography changes in ankylosing spondylitis patients on long-term adalimumab treatment
por: Yavuz, Nurce Cilesizoglu, et al.
Publicado: (2022)

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
por: Rudwaleit, Martin, et al.
Publicado: (2010)

Cost of Illness, Quality of Life, and Work Outcomes in Active Ankylosing Spondylitis Patients Treated With Adalimumab in China
por: Tu, Liudan, et al.
Publicado: (2020)

Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis
por: van der Heijde, D, et al.
Publicado: (2008)

Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years
por: van der Heijde, Désirée, et al.
Publicado: (2009)

Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis
por: Sieper, Joachim, et al.
Publicado: (2011)

A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis
por: Kobayashi, Shigeto, et al.
Publicado: (2011)

Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points
por: Su, Jinmei, et al.
Publicado: (2020)

Tumor Necrosis Factor-Alpha (+489 G/A) Polymorphism Can Predict the Response to Adalimumab in Chinese Han Patients With Ankylosing Spondylitis
por: Liang, Hong-Jin, et al.
Publicado: (2023)

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
por: van der Heijde, D, et al.
Publicado: (2008)

Phase III, multi-centre, randomised, double blind, Placebo-controlled study for treatment of juvenile ankylosing spondylitis (AS) with Adalimumab
por: Horneff, G, et al.
Publicado: (2011)

Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial
por: Su, Jinmei, et al.
Publicado: (2020)

Gene Expression Analysis before and after Treatment with Adalimumab in Patients with Ankylosing Spondylitis Identifies Molecular Pathways Associated with Response to Therapy
por: Dolcino, Marzia, et al.
Publicado: (2017)

Real-world evidence of the impact of adalimumab on work productivity and sleep measures in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
por: Tektonidou, Maria G., et al.
Publicado: (2020)

Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial
por: Wei, James Cheng-Chung, et al.
Publicado: (2020)

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
por: Francois, Fabien, et al.
Publicado: (2021)

Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis
por: van der Heijde, Désirée M, et al.
Publicado: (2009)

Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study
por: Rudwaleit, M, et al.
Publicado: (2008)

Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement
por: Horneff, Gerd, et al.
Publicado: (2012)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
por: Jiang, Yijia, et al.
Publicado: (2023)

Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab
por: van der Heijde, Désirée, et al.
Publicado: (2015)

Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization
por: Gils, Ann, et al.
Publicado: (2014)

Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence
por: Lombardi, G, et al.
Publicado: (2016)

A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab – a new side effect after 15 years of usage
por: Skuhala, Tomislava, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c4sig535qpu0a47ohp4vrfjtei